Communiqués Theracryf Plc

Actions

EVG

GB00BSVYN304

Recherche biotechnologique et médicale

Temps Différé London S.E. 12:54:36 09/09/2026			Varia. 5j.	Varia. 1 janv.
0,2000 ^GBX	+8,11%		+5,26%	-

20/08	Levée de fonds pour Theracryf ; les ventes de Potter & Moore à la peine	AN
14/05	RÉSULTATS ET TRADING : Nexus Infrastructure réduit sa perte au premier semestre	AN

Communiqués

14/05	Theracryf : Turner Pope Investments – Top-line Toxicology Data	PU
21/04	Theracryf : Turner Pope Investments – TheraCryf plc Research Note	PU
14/04	Theracryf : Turner Pope Investments – indicative proposal for Ox-1 / DAT programmes	PU
14/04	Theracryf : Capital Access Group – Ox-1/DAT programmes – indicative proposal	PU
13/04	Theracryf : Capital Access Group – Orexin M&A demonstrates industry appetite	PU
23/03	Theracryf : Capital Access Group – Ox-1 Imminent start of final toxicology study	PU
03/12	TheraCryf : Half-year results to 30 September 2025	PU
03/12	Theracryf : Interim Financial Results 2025	PU
03/12	TheraCryf : shares the latest corporate presentation following the release of the half-year report to 30 September 2025	PU
19/11	TheraCryf : shares the latest corporate presentation following London Life Sciences week.	PU
15/07/25	TheraCryf : LTIP Rules 2025	PU
10/07/25	Theracryf : Voting on AGM Resolutions	PU
10/07/25	TheraCryf : Presentation – Post AGM, July 2025	PU
16/06/25	Theracryf : Notice of AGM 2025	PU
16/06/25	TheraCryf : LTIP Rules 2025	PU
16/06/25	Theracryf : Annual Report and Accounts 2024-25	PU
05/06/25	Theracryf : Cavendish – Research Note on Full Year Results	PU
05/06/25	Theracryf : Capital Access Group – Research Note on Full Year Results	PU
05/06/25	Theracryf : Turner Pope Investments, Research Note on Full Year Results	PU
05/06/25	TheraCryf : presents annual results to March 2025	PU
14/05/25	Theracryf : Capital Access Group, Research – Pharmaron contract	PU
14/05/25	Theracryf : Cavendish, Research – CDMO/CRO Selection	PU
07/03/25	Theracryf : Voting on GM Resolution	PU
20/02/25	Theracryf : Notice of General Meeting and Form of Proxy	PU
20/02/25	Theracryf : Cavendish, Research	PU